News

Frontiers18d
Association between aquaporin 3 and transforming growth factor-beta 1 levels in decidual tissue and serum of patients with missed abortion
The membranes were then probed with primary antibodies: rabbit anti-human AQP3 (dilution 1:10; catalog no. YLA1093HU; Shanghai YL Biotech Co., Ltd.), rabbit anti-human TGF-β1 (dilution 1:30; catalog ...
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on ...
Keros Reinforces Commitment to Maximizing Stockholder Value
Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the ...
Study Finds on MSN3d
How Your Gums Could Be Sabotaging Your Heart Health
Your dentist's warnings about flossing aren't just about preventing bad breath and cavities. New research from Japan reveals ...
Targeted Oncology3d
Inside AGAVE-201: Axatilimab for Steroid-Refractory cGVHD
A panelist discusses how axatilimab, a humanized IgG4 monoclonal antibody targeting CSF-1 receptors on monocytes and macrophages, showed promising results in the AGAVE-201 trial for ...
The Manila Times5d
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ...
Science Daily2d
Marfan syndrome increases risk of brain alterations
A study reveals that inflammation associated with Marfan syndrome increases vulnerability to neurological diseases and complications following strokes, as demonstrated in animal models.
Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing ...
aTyr Pharma, Inc.: aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
Preclinical data demonstrate ATYR0101's unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respir ...
Medindia2d
ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
("ArkBio") today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibrosis (IPF). The study, led by Professor Huaping Dai ...
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced multiple ...
Marfan syndrome linked to increased brain inflammation and neurological risk
A study by the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) reveals that inflammation ...